- Home
- HOOK vs TXMD Comparison
HOOK vs TXMD Comparison
Compare HOOK & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- TXMD
- Stock Information
- Founded
- HOOK 2011
- TXMD 2008
- Country
- HOOK United States
- TXMD United States
- Employees
- HOOK N/A
- TXMD N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- HOOK Health Care
- TXMD Health Care
- Exchange
- HOOK Nasdaq
- TXMD Nasdaq
- Market Cap
- HOOK 15.3M
- TXMD 12.8M
- IPO Year
- HOOK 2019
- TXMD N/A
- Fundamental
- Price
- HOOK $1.20
- TXMD $1.22
- Analyst Decision
- HOOK Buy
- TXMD
- Analyst Count
- HOOK 4
- TXMD 0
- Target Price
- HOOK $10.67
- TXMD N/A
- AVG Volume (30 Days)
- HOOK 67.1K
- TXMD 37.9K
- Earning Date
- HOOK 08-07-2025
- TXMD 08-11-2025
- Dividend Yield
- HOOK N/A
- TXMD N/A
- EPS Growth
- HOOK N/A
- TXMD N/A
- EPS
- HOOK N/A
- TXMD N/A
- Revenue
- HOOK $9,351,000.00
- TXMD $1,841,000.00
- Revenue This Year
- HOOK N/A
- TXMD $427.09
- Revenue Next Year
- HOOK N/A
- TXMD N/A
- P/E Ratio
- HOOK N/A
- TXMD N/A
- Revenue Growth
- HOOK N/A
- TXMD 53.55
- 52 Week Low
- HOOK $0.72
- TXMD $0.70
- 52 Week High
- HOOK $6.77
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- HOOK 39.18
- TXMD 49.81
- Support Level
- HOOK $1.13
- TXMD $0.98
- Resistance Level
- HOOK $1.35
- TXMD $1.21
- Average True Range (ATR)
- HOOK 0.06
- TXMD 0.09
- MACD
- HOOK -0.01
- TXMD 0.01
- Stochastic Oscillator
- HOOK 40.64
- TXMD 82.48
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.